ASX-listed well being tech agency CardieX introduced it acquired Silicon Valley-based Blumio, Inc., a developer of cardiovascular sensor algorithms and information analytics instruments.
CardieX focuses on hypertension, cardiovascular well being and different arterial well being problems, whereas Blumio develops wearable sensor applied sciences centered on capturing cardiovascular information, together with blood stress measurements.
The acquisition follows a three-year collaboration between the businesses, which decided Blumio’s sensor know-how was suitable with CardieX subsidiary ATCOR’s SphygmoCor arterial technology that measures the central aortic stress waveform.
CardieX will even make the most of Blumio’s property to enhance its Arty Coronary heart Well being Analytics Platform in its CONNEQT Pulse and for its CONNEQT Band gadgets.
“Blumio brings a set of capabilities in wearable sensor growth, sign processing and massive information analytics experience that can profit each of our ATCOR and CONNEQT manufacturers, particularly in relation to the continued growth actions surrounding our CONNEQT Band. This acquisition is a pure extension of our core options that present a complete ecosystem of distinctive well being and wellness options centered on coronary heart well being,” CardieX Group CEO Craig Cooper mentioned in an announcement.
THE LARGER TREND
CardieX provides Blumio to its group of firms with various patented healthcare technologies.
In March, CardieX and AI-enabled wearable firm, Mobvoi, Inc. introduced the launch of its TicWatch GTH Pro, which leverages points of ATCOR’s coronary heart well being monitoring SphygmoCor know-how.